GSK-2330811 clinical trials
Also written GSK2330811.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses GSK-2330811 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GSK2330811
- 4
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses GSK-2330811 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's DiseaseWithdrawnPhase 2GlaxoSmithKlineNCT04151225Written as GSK2330811
- Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic SclerosisCompletedPhase 2GlaxoSmithKlineNCT03041025Written as GSK2330811
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese ParticipantsCompletedPhase 1GlaxoSmithKlineNCT04138043Written as GSK2330811
- A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT02386436Written as GSK2330811